Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
- Conditions
- Malignant Solid Tumors
- Interventions
- Drug: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06781125
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
- Conditions
- Herpes Zoster (HZ)Infectious DiseasesShingles
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 467
- Registration Number
- NCT06581575
- Locations
- πΊπΈ
Noble Clinical Research, Tucson, Arizona, United States
πΊπΈLong Beach Research Institute, Long Beach, California, United States
πΊπΈDM Clinical Research - Chicago, Chicago, Illinois, United States
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
- Conditions
- Infectious DiseaseRespiratory Syncytial Virus (RSV)
- Interventions
- Other: Placebo
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06564194
- Locations
- πΊπΈ
Health Awareness, Jupiter, Florida, United States
πΊπΈDelRicht - New Orleans, New Orleans, Louisiana, United States
πΊπΈSundance Clinical Research, Saint Louis, Missouri, United States
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
- Conditions
- Herpes Zoster (HZ)ShinglesInfectious Disease
- Interventions
- Biological: Active Control (Shingrix)
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05871541
- Locations
- πΊπΈ
CenExel RCA, Hollywood, Florida, United States
πΊπΈCenExel FCR, Tampa, Florida, United States
πΊπΈCenExel HRI, Berlin, New Jersey, United States
A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine
- Conditions
- Infectious DiseaseCOVID-19
- Interventions
- Other: Placebo
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT05743335
- Locations
- πΊπΈ
Velocity Clinical Research, Cedar Park, Texas, United States
- Prev
- 1
- 2
- Next